December 6, 2016

New Options for Benign Prostatic Hypertrophy (BPH) Changing the Treatment Paradigm

Office-based procedures carry little risk

650×450-prostate

By James Ulchaker, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The risks inherent in surgical removal of a benign enlarged prostate are well-known. Although many patients have a good outcome, some degree of incontinence or impotence can occur. Because BPH is not life-threatening, it is understandable why some men weigh the risks against the benefits and choose to forego treatment.

Fortunately, new, nonsurgical procedures are improving the experience for surgeons and patients alike.

No surgery required

We were involved in the clinical trials that led to FDA approval of the Rezūm® System (NxThera Inc., Maple Grove, Minnesota) in November 2015, and we now offer it in clinical practice and are proctoring colleagues being trained in the technique.

The Rezūm System employs convective water vapor energy to destroy hyperplastic glandular and stromal cells. Local anesthesia is used, and the procedure’s discomfort is minimal.

Advertisement

First, lidocaine is injected periprostatically. Lidocaine gel is then injected into the urethra, and a specially designed cystoscope is passed up the urethra to the prostate. About 0.42 milliliters of steam is injected into four to 10 zones on the prostate for nine seconds per zone. The procedure is completed in less than five minutes.

A urinary catheter is left in place for three days to compensate for swelling. Patients normally experience urgency and frequency for a period of time. Improvement in urine flow usually begins in about three weeks and is completed in three months.

What is known to date

Experience with the Rezūm System is limited to a handful of medical centers. In our experience, first in clinical trials and, subsequently, in clinical practice, the system has a high satisfaction rate and very low risk of side effects. Neither the ability to have an erection nor ejaculation appear to be significantly affected. Because the urinary sphincter is not damaged during the procedure, the risk of incontinence is very low.

Clinical trials of the Rezūm System were restricted to men with prostates of 80 grams or less. Its effectiveness in larger prostates is now being assessed. As of now, it appears that a single treatment is sufficient, but whether patients will need a second treatment in the future is unknown. We are now hoping to answer these questions in post-market studies.

Advertisement

The Rezūm System has ushered in a new era of patient-friendly treatments. Here at Cleveland Clinic, we are enrolling patients in trials of alternative systems, all with the potential for fewer side effects. As a specialist in BPH, I welcome the opportunity these procedures provide to improve the quality of life for my patients.

Related Articles

Drawing of surgeon's fingers pressing into a patient's body
March 15, 2024
Low Anterior Access Enhances Outcomes in Single-Port Robotic Urologic Surgeries

Pioneering and refining the approach in pyeloplasty, nephrectomy and more

Man examining prescription bottle in kitchen
February 27, 2024
Oral Medication Offers New Option for Testosterone Replacement

Unlike earlier pills, new drugs do not cause liver toxicity

URL_Pavelko_3777858_Urology_Dr. Lundy in Clinic_04-26-23_LDJ
January 30, 2024
Starting the Conversation About Male Infertility

Male factors play a role in about half of all infertility cases, yet men often are not evaluated

URL_Mould_3793308_Dr. Hadley Wood with patient at Q8_04-07-23_LD
December 1, 2023
Cleveland Clinic Urologist To Lead Esteemed Medical Journal

Hadley Wood, MD, shares her vision as the new editor-in-chief of Urology

sacral neuromodulation lead
October 9, 2023
Optimizing Outcomes in Sacral Neuromodulation for Overactive Bladder

Study leverages data from the ROSETTA trial

male urological anatomy
August 21, 2023
Aquablation Therapy Offers Alternative Approach for Benign Prostatic Hyperplasia

More on the procedure and the institutional experience

23-URL-3769861 CQD 650×450
June 22, 2023
The Complex Bacterial Colonization of Penile Implants

Study analyzes device biofilms, establishes basis for future developments

Ad